查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594380

多发性骨髓瘤药物市场：按药物、分布分类 - 全球预测 2025-2030

Multiple Myeloma Drug Market by Drug (Histone Deacetylase Inhibitors, Immunomodulating Agents, Monoclonal Antibodies), Distribution (Hospital Pharmacy, Online Channel, Retail Pharmacy) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

多发性骨髓瘤治疗市场2023年估值为227亿美元，预计到2024年将达到245.1亿美元，复合年增长率为8.04%，预计到2030年将达到390.2亿美元。

多发性骨髓瘤药物市场的定义是用于治疗称为多发性骨髓瘤的血癌的药物，其特征是骨髓中的恶性浆细胞。多发性骨髓瘤治疗对于疾病管理和改善患者的生活品质至关重要。治疗多发性骨髓瘤药物的需求源自于它们在延长存活期和减轻症状中所扮演的角色。药物类别包括蛋白酶体抑制剂、免疫调节剂和单株抗体，这些药物在一线和復发治疗方法中至关重要。最终使用者主要是医院、专科诊所和研究机构。市场成长受到发病率上升、生技药品进步和研发投资增加等因素的影响。此外，新兴市场中老年人口的不断增长和医疗保健服务范围的扩大进一步加剧了市场动态。最新的机会出现在个人化医疗方法和联合治疗中，特别是免疫查核点抑制剂，预计将提高疗效。公司可以透过策略联盟和扩大开拓人群的临床试验来利用这些机会。然而，这个市场面临着药物成本高、监管途径严格以及可能影响患者依从性的副作用等挑战。此外，竞争情势也是一个因素，例如主要药品专利到期导致生物相似药大量涌入。需要技术创新的领域包括CAR T细胞疗法等下一代治疗方法和奈米载体技术等新型药物传输系统。这些创新提高了治疗特异性、减少副作用并支持市场扩张。该市场表现出双重性质，受到科学创新的支持，但受到经济和监管障碍的限制。与法律规范的策略协调、对尖端研发的投资以及利用与多发性骨髓瘤药物市场中的生物技术公司的伙伴关係正在推动可持续的业务成长和改善患者的治疗效果。

主要市场统计
基准年[2023] 227亿美元
预测年份 [2024] 245.1亿美元
预测年份 [2030] 390.2亿美元
复合年增长率（%） 8.04%

市场动态：揭示快速发展的多发性骨髓瘤药物市场的关键市场洞察

供需的动态交互作用正在改变多发性骨髓瘤药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 多发性骨髓瘤的适应症和盛行率不断增加
    • 支持已开发国家治疗的有吸引力的报销政策
    • 学名药核准了药物供应
  • 市场限制因素
    • 严格的医药品认证过程
  • 市场机会
    • 产品开发、临床试验和商业化的共同开发
    • 采用标靶治疗和皮质类固醇
  • 市场挑战
    • 可能的副作用

波特五力：驾驭多发性骨髓瘤药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解多发性骨髓瘤药物市场的外部影响

外部宏观环境因素在塑造多发性骨髓瘤治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解多发性骨髓瘤治疗药物市场的竞争状况

多发性骨髓瘤治疗市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵多发性骨髓瘤治疗市场供应商的绩效评估

FPNV定位矩阵是评估多发性骨髓瘤治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划多发性骨髓瘤药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对多发性骨髓瘤治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 多发性骨髓瘤的适应症和盛行率不断增加
      • 有吸引力的报销政策支持已开发国家的治疗
      • 学名药的核准增加了药品的可得性
    • 抑制因素
      • 严格的医药品认证过程
    • 机会
      • 协调产品开发、药物测试和商业化
      • 标靶治疗和皮质类固醇的介绍
    • 任务
      • 潜在的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 多发性骨髓瘤治疗药物市场（依药物）

  • 组蛋白去乙酰化酶抑制剂
  • 免疫调节剂
  • 单株抗体
  • 蛋白酶体抑制剂

第七章 多发性骨髓瘤治疗药物市场经销商

  • 医院药房
  • 线上管道
  • 零售药房

第八章美洲多发性骨髓瘤药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区多发性骨髓瘤药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东及非洲多发性骨髓瘤药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Accurex Health Care Manufacturing Inc.
  • Amgen Inc.
  • Bayer AG
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Intas Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-036C5CF3A894

The Multiple Myeloma Drug Market was valued at USD 22.70 billion in 2023, expected to reach USD 24.51 billion in 2024, and is projected to grow at a CAGR of 8.04%, to USD 39.02 billion by 2030.

The multiple myeloma drugs market is defined by pharmaceuticals used to treat the blood cancer known as multiple myeloma, characterized by malignant plasma cells in the bone marrow. These drugs are vital for disease management and improving patient quality of life. The necessity of multiple myeloma drugs stems from their role in prolonging survival rates and minimizing symptoms. Drug categories include proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, which are critical for frontline and relapsed treatment regimens. End-users primarily consist of hospitals, specialty clinics, and research institutions. Market growth is influenced by factors such as rising incidence rates, advancements in biologics, and increasing investment in R&D. Moreover, a growing geriatric population and expanding access to healthcare in developing regions further accentuate market dynamics. Latest opportunities are seen in personalized medicine approaches and combination therapies, notably with immune checkpoint inhibitors, that promise enhanced efficacy. Businesses can capitalize on these opportunities through strategic collaborations and expanding clinical trials in underexplored demographics. However, the market faces challenges such as high drug costs, stringent regulatory pathways, and potential adverse effects, which may affect patient compliance. Limitations also come from the competitive landscape with the patent expiration of key drugs leading to the influx of biosimilars. Areas ripe for innovation include next-generation therapies such as CAR T-cell treatments and novel drug delivery systems like nanocarrier technology. These innovations can improve therapy specificity and reduce side effects, boosting market expansion. The market exhibits a dual nature, buoyed by scientific innovations yet constrained by economic and regulatory hurdles. Strategic alignment with regulatory frameworks, investment in cutting-edge R&D, and leveraging partnerships with biotech firms could be effective avenues for sustainable business growth and enhanced patient outcomes in the multiple myeloma drugs market.

KEY MARKET STATISTICS
Base Year [2023] USD 22.70 billion
Estimated Year [2024] USD 24.51 billion
Forecast Year [2030] USD 39.02 billion
CAGR (%) 8.04%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multiple Myeloma Drug Market

The Multiple Myeloma Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased indication and prevalence of Multiple Myeloma
    • Attractive reimbursement policies supporting treatments in developed countries
    • Increased drug availability along with approvals for generics
  • Market Restraints
    • Stringent drug approval process
  • Market Opportunities
    • Collaborating product development and drug trials and commercialization
    • Targeted therapy and adoption of Corticosteroids
  • Market Challenges
    • Potential side effects

Porter's Five Forces: A Strategic Tool for Navigating the Multiple Myeloma Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multiple Myeloma Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multiple Myeloma Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multiple Myeloma Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multiple Myeloma Drug Market

A detailed market share analysis in the Multiple Myeloma Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multiple Myeloma Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multiple Myeloma Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Multiple Myeloma Drug Market

A strategic analysis of the Multiple Myeloma Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Multiple Myeloma Drug Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accurex Health Care Manufacturing Inc., Amgen Inc., Bayer AG, Bristol Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche AG, Intas Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG, Ono Pharmaceutical Co., Ltd., Pfizer Inc., Sandoz International GmbH, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Multiple Myeloma Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Histone Deacetylase Inhibitors, Immunomodulating Agents, Monoclonal Antibodies, and Proteasome Inhibitors.
  • Based on Distribution, market is studied across Hospital Pharmacy, Online Channel, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased indication and prevalence of Multiple Myeloma
      • 5.1.1.2. Attractive reimbursement policies supporting treatments in developed countries
      • 5.1.1.3. Increased drug availability along with approvals for generics
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent drug approval process
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborating product development and drug trials and commercialization
      • 5.1.3.2. Targeted therapy and adoption of Corticosteroids
    • 5.1.4. Challenges
      • 5.1.4.1. Potential side effects
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multiple Myeloma Drug Market, by Drug

  • 6.1. Introduction
  • 6.2. Histone Deacetylase Inhibitors
  • 6.3. Immunomodulating Agents
  • 6.4. Monoclonal Antibodies
  • 6.5. Proteasome Inhibitors

7. Multiple Myeloma Drug Market, by Distribution

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Online Channel
  • 7.4. Retail Pharmacy

8. Americas Multiple Myeloma Drug Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Multiple Myeloma Drug Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Myeloma Drug Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Accurex Health Care Manufacturing Inc.
  • 3. Amgen Inc.
  • 4. Bayer AG
  • 5. Bristol Myers Squibb Company
  • 6. Celgene Corporation
  • 7. F. Hoffmann-La Roche AG
  • 8. Intas Pharmaceuticals Limited
  • 9. Johnson & Johnson Services, Inc.
  • 10. Nichi-Iko Pharmaceutical Co., Ltd.
  • 11. Novartis AG
  • 12. Ono Pharmaceutical Co., Ltd.
  • 13. Pfizer Inc.
  • 14. Sandoz International GmbH
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. MULTIPLE MYELOMA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIPLE MYELOMA DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTIPLE MYELOMA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MULTIPLE MYELOMA DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE CHANNEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2023